The U.S. Food and Drug Administration (FDA) will make a decision on awarding marketing approval for Rolontis, the first new biotech drug candidate of Hanmi Pharmaceutical, in September. According to the FDA’s Prescription Drug User Fee Act (PDUFA), Rolontis’ approval deadline is set at Sept. 9.The F
HanmiGlobal, a construction project management (PM) company, announced on July 14 that it has signed a memorandum of understanding (MOU) with Cadmus Group, a U.S. disaster and safety management consulting company.Cadmus Group is currently operating a crisis management center in the White House, and
Korea CXO Institute announced on July 13 that the combined market cap of 2,441 companies listed in South Korea dropped from 2,575 trillion won to 2,095 trillion won in the first half of this year and more than 80 percent of the companies showed a decrease in market cap in that period.“With the stock
HanmiGlobal announced on July 12 that it has taken over Walker Sime, a British project management (PM) company.Founded in 1999 in Manchester, northeastern England, Walker Sime provides specialized services such as construction project management, cost management, and architectural design management,
The authors are analysts of NH Investment & Securities. They can be reached at hwdoh@nhqv.com and jiyong.im@nhqv.com, respectively. -- Ed. IMW 2022 featured presentations on several next-gen technologies, including 25nm pitch 3D NAND, 7-bit NAND cells, and 3D Fe-NAND. Moving ahead, it is expected th
Hanmi Pharmaceutical's innovative new drug for acute myeloid leukemia (AML) has won a Fast Track designation from the U.S. FDA. The new drug, HM43239, was licensed out to Aptose, a U.S. biotech company listed on the NASDAQ, in November 2021.“The FDA’s Fast Track designation is a recognition of t
The K-mRNA Consortium, launched in June last year, is failing due to clinical trial delays and members’ move to go alone.Hanmi Pharmaceutical and GC Pharma are expanding their own mRNA business these days. Specifically, the former is planning to invest 10 billion won in drug substance manufacturing
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Hanmi Pharm posted consolidated 1Q22 sales of W321.1bn and OP of W38.7bn, in line with our estimates, thanks to Beijing Hanmi and business normalization amid the easing of the Covid-19 pandemic. Glob
Lim Ju-hyun, president of Hanmi Pharmaceutical, has been appointed as a director of its U.S. partner Spectrum Pharmaceuticals.Spectrum officially announced the appointment of Lim as one of its directors on March 11. It explained that Lim will play a big role in promoting cooperation between the two
The author is an analyst of NH Investment & Securities. He can be reached at hwdoh@nhqv.com. -- Ed. Graphcore has collaborated with TSMC to unveil the first AI processor that utilizes the SoIC-WoW process, which applies hybrid bonding and rear TSV technology. Related players include BESI, Fujimi, an
The Korea Federation of Banks announced on March 8 that the average annual salary of Citibank Korea staff members was 120 million won last year, the highest in the domestic banking sector.Citibank Korea has been at the top of the list all the way since 2014. The members reached an annual salary of 1
Hanmi Pharmaceutical’s osteoarthritis treatment injection Hyaluma went on sale in the United States on March 1.The Korean drugmaker announced on March 7 that it has started selling Hyaluma throughout the United States in partnership with Arthrex, a global medical device company.Athrex distributes ro
Hanmi Pharmaceutical announced on Jan. 20 that it will speed up the production of a generic version of Merck & Co.'s COVID-19 pill, molnupiravir (product name: Lagevrio), for supply to 105 low- and middle-income countries.Hanmi Pharmaceutical is one of the three Korean generic drug manufacturers
Hanmi Pharmaceutical announced its R&D plan for this year, including some 30 new drug pipelines currently under development, at the 40th J.P. Morgan Healthcare Conference on Jan. 12 (U.S. local time).The drugmaker also revealed its strategy to develop various new drugs, including a COVID-19 vaccine,
The author is an analyst of NH Investment & Securities. He can be reached at hwdoh@nhqv.com. -- Ed. TSMC is aiming at 2022 sales growth in the mid/high-20% range and capex increase of 40% y-y to US$42bn. We expect the global semiconductor equipment sector to benefit.TSMC predicting mid/high-20% sale
Hanmi Pharmaceutical will produce ZyCoV-D, a plasmid deoxyribonucleic acid (pDNA) COVID-19 vaccine developed by Indian pharmaceutical company Zydus Cadila.The company announced on Jan. 11 that it has signed a technology transfer and facility preparation contract with Enzychem Lifesciences, which con
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Hanmi Pharm is expected to post consolidated 4Q21 sales of W334.5bn and OP of W32.5bn. We cut our target EV/EBITDA multiple for domestic pharmaceutical peers and lower our estimate for the company’s
Hanmi Pharmaceutical has exported a new drug candidate, which it licensed from a U.S. company six years ago, to a Chinese corporation.This is the first time that Hanmi Pharmaceutical has exported a new drug technology acquired from outside.Hanmi Pharmaceutical announced on Jan. 3 that it signed a co
South Korean companies are developing their printed circuit board products and equipment for a lower reliance on imported ones. At present, Japanese companies’ share in the PCB manufacturing equipment market is more than 90 percent.Hanmi Semiconductor recently developed PCB cutters on its own. Previ
The author is an analyst of NH Investment & Securities. He can be reached at hwdoh@nhqv.com. -- Ed. While a memory market downcycle is likely to last from 4Q21 to 2022, such expectations have already been reflected in chipmakers’ share prices, which have pulled back over the last 10 months. Given th